Search

everythinglearnresearchcommunity

for

Search:↓

Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.

JAK inhibitors show promise for treating skin diseases effectively and safely.

Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.

Adalimumab improved folliculitis decalvans in most patients.

SIG-1451 could be a promising new treatment for atopic dermatitis.

Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.

Topical tofacitinib shows promise as a future treatment for alopecia areata.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.

JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.

JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.

A man had a rare skin reaction from a hair loss medication, which improved after stopping the drug.

A patient's grey hair regained color during treatment with adalimumab.

Canakinumab's effect on COVID-19 outcomes is unclear.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

A woman developed psoriasis after taking certolizumab pegol, improving after stopping the drug and starting other treatments.

Tofacitinib helped a woman regrow hair with no major side effects.